Interprofessional Pharmacogenomics (IPGx) Registry and Repository
Launched by TEXAS A&M UNIVERSITY · Dec 5, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Interprofessional Pharmacogenomics (IPGx) Registry and Repository is a clinical trial that aims to collect genetic and health information to help doctors select the most suitable medications for patients. This study is particularly relevant for individuals dealing with conditions like diabetes, cholesterol issues, cancer, heart disease, and respiratory illnesses such as COPD. The trial is currently recruiting participants who are over 18 years old and take five or more medications, including over-the-counter drugs and supplements. It may also include those on specific blood pressure or depression medications.
Participants in this study can expect to provide blood and urine samples, answer detailed questionnaires about their health, and have their medical records monitored for five years. This information will be shared with researchers in a way that keeps personal details private. It's important to note that individuals who are in hospice care, unable to provide consent, or have certain severe cognitive conditions like Alzheimer's disease are not eligible to join. If you’re interested in how your genetic makeup can impact your medication choices, this trial might be a good fit for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
- • Individuals taking blood pressure or depression medications, even if less than five medications.
- • Ability to understand and give consent.
- • Able to consent to donate blood and/or urine samples and buccal swabs.
- • Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
- • Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
- • All genders.
- • Any age over 18 years.
- Exclusion Criteria:
- • Individuals admitted to hospice.
- • Declines to participate or interact with staff/share their medical status.
- • A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
- • Individuals who are unable or unwilling to provide consent.
- • Unable to verbally communicate and comprehend English language
About Texas A&M University
Texas A&M University, a leading research institution located in College Station, Texas, is dedicated to advancing knowledge and innovation in various fields, including health sciences. As a prominent clinical trial sponsor, Texas A&M University leverages its extensive resources and expertise to conduct rigorous research aimed at improving patient outcomes and addressing critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and students, ensuring a comprehensive approach to clinical trials that emphasizes ethical standards, scientific integrity, and community impact. Through its commitment to advancing medical research, Texas A&M University plays a vital role in the development of novel therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bryan, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported